Current Edition

The Challenges and Benefits of Biosimilar Drug Development for Trastuzumab, a Precision Medicine

Monoclonal antibodies (mAb) are among the most promising biologic
drugs currently on the market for treatment of life-threatening
diseases. The selectivity and specificity of these mAbs resulted in
the first generation of targeted therapies. In this piece, Oxana Iliach,
Winfred Shaw, Raymond A. Huml and Nigel Rulewski of Quintiles
analyse how this is an innovative approach to disease prevention
and treatment that takes into account differences in people’s genes,
environments and lifestyles. Trastuzumab provided the first potential
mAb oncology precision medicine to be approved by the FDA.